2505 MERIDIAN PARKWAY, SUITE 100, DURHAM, NC
Reports Fourth Quarter and Year End 2024 Financial Results
Amended material disclosure
To Acquire, Further Diversifying Oncology Portfolio
Other Events
Material disclosure
Investor Presentation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Financial Results, Reg. FD
Amended Annual Report
FY 2024
Q3
Q2
Q1
FY 2023
Notice of Suspension of Duty to File Reports
Effectiveness Notice
Schedule 14D-9C Solicitation/Recommendation Statement Communication
Solicitation/Recommendation Statement
Tender Offer Statement by Third Party
Tender Offer Statement by Issuer
Additional Proxy Materials
Definitive Proxy Statement
Notification Filed by a National Security Exchange
Statement of Changes in Beneficial Ownership
S-8 POS